New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 20, 2014
10:45 EDTWMGI, WMGI, WMGIWright Medical has a conference call hosted by JPMorgan
JPMorgan Analyst Weinstein will host a conference call with CEO Bob Palmisano on June 27 at 11 am.
News For WMGI From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
September 2, 2015
07:54 EDTWMGIWright Medical approval one of two main catalysts, says Leerink
Leerink analyst Richard Newitter views the FDA approval of Augment as one of two main upcoming catalysts for Wright Medical (WMGI). The second is the Tornier (TRNX) deal closing, which the analyst thinks could also occur this quarter. Newitter says an overhang has been removed with the approval and reiterates an Outperform rating on Wright with a $31 price target.
06:07 EDTWMGIPiper sees little upside to Wright Medical target despite FDA approval
Piper Jaffray analyst Matt O'Brien calls news of Wright Medical's regulatory clearance for Augment surprising and "clearly a positive." Most had expected approval to be delayed until the end of 2015, the analyst tells investors in a research note. Nonetheless, O'Brien sees little upside to his price target of $27 and keeps a Neutral rating on Wright. He expects the stock to rally about 10% today on last night's news.
September 1, 2015
18:41 EDTWMGIOn The Fly: After Hours Movers
Subscribe for More Information
16:02 EDTWMGIWright Medical subsidiary receives FDA approval for its PMA for AUGMENT
Wright Medical Group announced that its BioMimetic subsidiary has received an approval order from the FDA for its Premarket Approval Application, or PMA, for AUGMENT Bone Graft. The approval order indicates that FDA determined that AUGMENT Bone Graft is safe and effective as an alternative to autograft for ankle and/or hindfoot fusion indications. Wright can now initiate commercial sale and distribution of AUGMENT Bone Graft in the U.S. The Company continues to anticipate AUGMENT revenue in the U.S. to be in the range of $10M-$12M in the first seven to eight months post-approval.

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use